WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

This group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.


H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H01C HYPOTHALAMIC HORMONES

This group comprises hypothalamic hormones; extracts, purified natural hormones and synthetic analogues.
Hypothalamic hormones used as diagnostic agents for pituitary function are classified in V04CD.


H01CA Gonadotropin-releasing hormones

Buserelin, goserelin, histrelin, leuprorelin, and triptorelin are classified in L02AE Gonadotropin releasing hormone analogues.
Gonadorelin used as diagnostic agent is classified in V04CM.

The DDD of nafarelin is based on the treatment of endometriosis. No other DDDs have been assigned, due to the highly variable dosages used.

H01CB Somatostatin and analogues

Somatostatin, octreotide and lanreotide, which are also used in cancer, are classified in this group.

The DDDs of octreotide and lanreotide are based on the treatment of acromegaly.

H01CC Anti-gonadotropin-releasing hormones

Last updated: 2024-01-26